Randomized head-to-head comparison of pitavastatin, atorvastatin, and rosuvastatin for safety and efficacy (quantity and quality of LDL) - The PATROL trial-

Circulation Journal

Volumn 75, Issue 6, 2011, Pages 1493-1505

  Saku, Keijiro ^a,b   Zhang, Bo ^a   Noda, Keita ^b  

^a FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b FUKUOKA UNIVERSITY   (Japan)

Author keywords

Atorvastatin; Efficacy; Pitavastatin; Rosuvastatin; Safety

Indexed keywords

ATORVASTATIN; ENZYME; HEMOGLOBIN A1C; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PITAVASTATIN; ROSUVASTATIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ATOPIC DERMATITIS; BACKACHE; BILIRUBIN BLOOD LEVEL; CONSTIPATION; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DIARRHEA; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ECZEMA; ENZYME BLOOD LEVEL; ERYTHROCYTE COUNT; FEMALE; FEVER; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GASTRITIS; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; KIDNEY FUNCTION; LABORATORY TEST; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOCYTE COUNT; LIPOPROTEIN BLOOD LEVEL; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTICENTER STUDY; MUSCLE SPASM; MUSCULOSKELETAL STIFFNESS; MYALGIA; PATIENT COMPLIANCE; PERIORBITAL EDEMA; POTASSIUM BLOOD LEVEL; PROTEINURIA; PRURITUS; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SIDE EFFECT; SKELETAL MUSCLE; SKIN ALLERGY; UREA NITROGEN BLOOD LEVEL; URIC ACID BLOOD LEVEL;

AGED; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; CHOLESTEROL, LDL; FEMALE; FLUOROBENZENES; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; JAPAN; MALE; MIDDLE AGED; PATIENT SELECTION; PROSPECTIVE STUDIES; PYRIMIDINES; PYRROLES; QUINOLINES; SULFONAMIDES; TIME FACTORS; TREATMENT OUTCOME;

EID: 79957778475     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-10-1281     Document Type: Article

References (33)

1. Nakamura H, Arakawa K, Itakura H, Kitabatake A, Goto Y, Toyota T, et al; MEGA Study Group. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): A prospective randomised controlled trial. Lancet 2006; 368: 1155-1163.
2. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al; JUPITER Trial Study Group. Reduction in Creactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: A prospective study of the JUPITER trial. Lancet 2009; 373: 1175-1182.
3. Okazaki S, Yokoyama T, Miyauchi K, Shimada K, Kurata T, Sato H, et al. Early statin treatment in patients with acute coronary syndrome: Demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: The ESTABLISH Study. Circulation 2004; 110: 1061-1068.
4. Takayama T, Hiro T, Yamagishi M, Daida H, Hirayama A, Saito S, Y, et al; COSMOS Investigators. Effect of rosuvastatin on coronary atheroma in stable coronary artery disease: Multicenter coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects (COSMOS). Circ J 2009; 73: 2110-2117.
5. Neuvonen PJ, Backman JT, Niemi M. Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin. Clin Pharmacokinet 2008; 47: 463-474.
6. Martin PD, Mitchell PD, Schneck DW. Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers. Br J Clin Pharmacol 2002; 54: 472-477.
7. Japanese Society of Hospital Pharmacists. Interview Form (Lipitor). http://products.pfizer.co.jp/documents/if/lip/lip01_if.htm (accessed December 20, 2010).
8. Japanese Society of Hospital Pharmacists. Interview Form (Crestor). http://med.astrazeneca.co.jp/crestor/ (accessed December 20, 2010).
9. Japanese Society of Hospital Pharmacists. Interview Form (Livalo). http://www.livalo.com/sitemap.htm (accessed December 20, 2010).
10. Lee E, Ryan S, Birmingham B, Zalikowski J, March R, Ambrose H, et al. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther 2005; 78: 330-341.
11. Japan Atherosclerosis Society (JAS). Guidelines for Diagnosis and Treatment of Atherosclerotic Cardiovascular Diseases. Tokyo: Japan Atherosclerosis Society, 2002.
12. Zhang B, Matsunaga A, Rainwater DL, Miura S, Noda K, Nishikawa H, et al. Effects of rosuvastatin on electronegative LDL as characterized by capillary isotachophoresis: The ROSARY Study. J Lipid Res 2009; 50: 1832-1841.
13. Zhang B, Kaneshi T, Ohta T, Saku K. Relation between insulin resistance and fast-migrating LDL subfraction as characterized by capillary isotachophoresis. J Lipid Res 2005; 46: 2265-2277.
14. Zhang B, Uehara Y, Hida S, Miura S, Rainwater DL, Segawa M, et al. Effects of reconstituted HDL on charge-based LDL subfractions as characterized by capillary isotachophoresis. J Lipid Res 2007; 48: 1175-1189.
15. Zhang B, Matsunaga A, Saku K, Nakano S, Yamada T. Associations among plasma lipoprotein subfractions as characterized by analytical capillary isotachophoresis, apolipoprotein E phenotype, Alzheimer disease, and mild cognitive impairment. Arterioscler Thromb Vasc Biol 2004; 24: e144-e146.
16. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Japanese version. http://www.jcog.jp/doctor/tool/CTCAEv3J_070308.pdf#search='CTCAE (accessed December 22, 2010).
17. Danchin N, Chadarevian R, Gayet JL, Licour M, Valensi P. Compared with atorvastatin at the dose of 10 mg per day rosuvastatin was more effective to reach an LDL goal of <1.00 g/l in high cardiovascular risk patients (ARIANE study). Ann Cardiol Angeiol (Paris) 2007; 56: 82-87.
18. Leiter LA, Rosenson RS, Stein E, Reckless JP, Schulte KL, Schleman M, et al; POLARIS study investigators. Efficacy and safety of rosuvastatin 40 mg versus atorvastatin 80 mg in high-risk patients with hypercholesterolemia: Results of the POLARIS study. Atherosclerosis 2007; 194: e154-e164.
19. Wlodarczyk J, Sullivan D, Smith M. Comparison of benefits and risks of rosuvastatin versus atorvastatin from a meta-analysis of head-to-head randomized controlled trials. Am J Cardiol 2008; 102: 1654-1662.
20. Yokote K, Bujo H, Hanaoka H, Shinomiya M, Mikami K, Miyashita Y, et al. Multicenter collaborative randomized parallel group comparative study of pitavastatin and atorvastatin in Japanese hypercholesterolemic patients: Collaborative study on hypercholesterolemia drug intervention and their benefits for atherosclerosis prevention (CHIBA study). Atherosclerosis 2008; 201: 345-352.
21. Lee SH, Chung N, Kwan J, Kim DI, Kim WH, Kim CJ, et al. Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: An 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia. Clin Ther 2007; 29: 2365-2373.
22. Toi T, Taguchi I, Yoneda S, Kageyama M, Kikuchi A, Tokura M, et al. Early effect of lipid-lowering therapy with pitavastatin on regression of coronary atherosclerotic plaque: Comparison with atorvastatin. Circ J 2009; 73: 1466-1472.
23. Nakata M, Nagasaka S, Kusaka I, Matsuoka H, Ishibashi S, Yada T. Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): Implications in glycaemic control. Diabetologia 2006; 49: 1881-1892.
24. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359: 2195-2207.
25. Yamakawa T, Takano T, Tanaka S, Kadonosono K, Terauchi Y. Influence of pitavastatin on glucose tolerance in patients with type 2 diabetes mellitus. J Atheroscler Thromb 2008; 15: 269-275.
26. Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, et al. Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials. Lancet 2010; 375: 735-742.
27. Baker SK, Tarnopolsky MA. Statin-associated neuromyotoxicity. Timely Top Med Cardiovasc Dis 2005; 9: E26.
28. Karpisek M, Stejskal D, Kotolova H, Kollar P, Janoutova G, Ochmanova R, et al. Treatment with atorvastatin reduces serum adipocyte-fatty acid binding protein value in patients with hyperlipidaemia. Eur J Clin Invest 2007; 37: 637-642.
29. Milionis HJ, Kakafika AI, Tsouli SG, Athyros VG, Bairaktari ET, Seferiadis KI, et al. Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemia. Am Heart J 2004; 148: 635-640.
30. Kimura K, Shimano H, Yokote K, Urashima M, Teramoto T. Effects of pitavastatin (LIVALO tablet) on the estimated glomerular filtration rate (eGFR) in hypercholesterolemic patients with chronic kidney disease: Sub-analysis of the LIVALO Effectiveness and Safety (LIVES) Study. J Atheroscler Thromb 2010; 17: 601-609.
31. Barter PJ, Brandrup-Wognsen G, Palmer MK, Nicholls SJ. Effect of statins on HDL-C: A complex process unrelated to changes in LDL-C: Analysis of the VOYAGER Database. J Lipid Res 2010; 51: 1546-1553.
32. Muravyov AV, Yakusevich VV, Surovaya L, Petrochenko A. The effect of simvastatin therapy on hemorheological profile in coronary heart disease (CHD) patients. Clin Hemorheol Microcirc 2004; 31: 251-256.
33. Nara M, Sumino H, Nara M, Machida T, Amagai H, Nakajima K, et al. Impaired blood rheology and elevated remnant-like lipoprotein particle cholesterol in hypercholesterolaemic subjects. J Int Med Res 2009; 37: 308-317.